Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2026-01-04 @ 5:05 PM
Study NCT ID:
NCT06682169
Status:
RECRUITING
Last Update Posted:
2025-12-08
First Post:
2024-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-11-20
Start Date Type:
ACTUAL
Primary Completion Date:
2029-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-11-06
First Submit QC Date:
None
Study First Post Date:
2024-11-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-05
Last Update Post Date:
2025-12-08
Last Update Post Date Type:
ESTIMATED